Imipenem/Cilastatine Tamrisa (Cilastatin, Imipenem)

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, which prevents cross‑linking of peptidoglycan strands and leads to bacterial lysis. Cilastatin, co‑formulated, blocks renal dehydropeptidase I, an enzyme that would otherwise degrade imipenem, thereby preserving its antibacterial activity and increasing urinary concentrations.

The dosage of Imipenem/Cilastatin Tamrisa is individualized by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. Healthcare professionals determine the appropriate infusion rate and total daily dose according to established guidelines and patient-specific considerations.

The safety of Imipenem/Cilastatin in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant. Clinicians should evaluate the risk‑benefit profile and consider alternative therapies when possible.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Imipenem/cilastatin offers a broad spectrum of activity against Gram‑negative, Gram‑positive and anaerobic bacteria, similar to other carbapenems such as meropenem or ertapenem. Its unique combination with cilastatin protects the drug from renal degradation, potentially providing higher urinary concentrations. Choice among carbapenems depends on local resistance patterns, pharmacokinetic considerations, and patient‑specific factors.

Imipenem/Cilastatin Tamrisa should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. Maintaining the cold chain preserves drug stability and efficacy.

The medication is supplied as a sterile powder for reconstitution and is administered by intravenous infusion. After reconstitution with the appropriate diluent, the solution is infused over a specified period, typically 30 minutes to 1 hour, under aseptic conditions by qualified healthcare personnel.

Serious adverse events include seizures, especially in patients with pre‑existing CNS disorders or renal impairment, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Monitoring for neurological symptoms, hypersensitivity signs, and gastrointestinal disturbances is essential during therapy.

Patients with a known hypersensitivity to imipenem, cilastatin, or any other carbapenem antibiotics should not receive this product. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving concomitant valproic acid, as the drug may reduce valproate levels.